Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on KalVista (KALV) to $27 from $19 and keeps an Outperform rating on the shares. Ekterly is poised for a strong launch given the unmet need, clinical profile, and desire from patients for an oral on-demand therapy, though KalVista priced the drug higher than current injectables, which range from ~$4K-$11K per dose and ~$11K-$17K per attack, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV:
- KalVista price target raised to $20 from $18 at Leerink
- Buy Rating for KalVista Pharmaceuticals Driven by FDA Approval and Strategic Market Entry of Ekterly
- KalVista price target raised to $40 from $32 at Jefferies
- Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz
- KalVista Pharmaceuticals Gains FDA Approval for EKTERLY®